181 related articles for article (PubMed ID: 26093520)
1. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.
Ninomiya K; Hotta K; Hisamoto-Sato A; Ichihara E; Gotoda H; Morichika D; Tamura T; Kayatani H; Minami D; Kubo T; Tabata M; Tanimoto M; Kiura K
Int J Clin Oncol; 2016 Feb; 21(1):81-7. PubMed ID: 26093520
[TBL] [Abstract][Full Text] [Related]
2. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002.
Hotta K; Takigawa N; Hisamoto-Sato A; Ichihara E; Kudo K; Uchida K; Yanase-Nakamura K; Tanaka H; Kato Y; Tabata M; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2013 Nov; 43(11):1115-23. PubMed ID: 24082005
[TBL] [Abstract][Full Text] [Related]
3. Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study.
Horinouchi H; Kubota K; Itani H; Taniyama TK; Nakamichi S; Wakui H; Kanda S; Nokihara H; Yamamoto N; Sekine I; Tamura T
Jpn J Clin Oncol; 2013 Nov; 43(11):1105-9. PubMed ID: 24006505
[TBL] [Abstract][Full Text] [Related]
4. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
[TBL] [Abstract][Full Text] [Related]
5. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
[TBL] [Abstract][Full Text] [Related]
6. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies.
Nishii K; Hotta K; Ninomiya K; Kato Y; Ichihara E; Ohashi K; Ninomiya T; Kubo T; Rai K; Tabata M; Maeda Y; Kiura K
Respir Investig; 2019 Sep; 57(5):460-465. PubMed ID: 31186170
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer-a retrospective study.
Aoyama T; Tsunoda T; Kato H; Hagino A; Furutani R; Ito K; Yoshioka H; Nakamura M; Hiraide M; Kawakami K; Kobayashi K; Suzuki K; Ichimura T; Yamaguchi K; Hama T
J Chemother; 2020 May; 32(3):144-150. PubMed ID: 31960769
[TBL] [Abstract][Full Text] [Related]
9. Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis.
Yamaguchi T; Uozu S; Isogai S; Hayashi M; Goto Y; Nakanishi T; Imaizumi K
Support Care Cancer; 2017 Apr; 25(4):1215-1220. PubMed ID: 27966021
[TBL] [Abstract][Full Text] [Related]
10. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
12. [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
Ohhara Y; Isobe H; Ito K; Fuke S; Kojima T; Saito H; Nishiura Y
Gan To Kagaku Ryoho; 2015 Jan; 42(1):57-61. PubMed ID: 25596680
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.
Fukuda M; Soda H; Fukuda M; Kinoshita A; Nakamura Y; Nagashima S; Takatani H; Tsukamoto K; Kohno S; Oka M
Cancer; 2007 Aug; 110(3):606-13. PubMed ID: 17577234
[TBL] [Abstract][Full Text] [Related]
14. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
15. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
Tiseo M; Martelli O; Mancuso A; Sormani MP; Bruzzi P; Di Salvia R; De Marinis F; Ardizzoni A
Tumori; 2007; 93(2):138-44. PubMed ID: 17557559
[TBL] [Abstract][Full Text] [Related]
16. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
[TBL] [Abstract][Full Text] [Related]
17. Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non-small-cell lung cancer: A retrospective cohort study (HYCIS-XL).
Niggebrugge-Mentink KL; Beex-Oosterhuis MM; Ter Horst PGJ; van de Poll MEC; Dieleman HG; van Kesteren C
J Clin Pharm Ther; 2020 Oct; 45(5):1153-1158. PubMed ID: 32533904
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.
Hong J; Jung M; Kim YJ; Sym SJ; Kyung SY; Park J; Lee SP; Park JW; Cho EK; Jeong SH; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2012 Jan; 69(1):215-20. PubMed ID: 21691745
[TBL] [Abstract][Full Text] [Related]
19. [Nephrotoxicity of a Short Hydration Method for the Cisplatin Regimen in Patients with Gastric Cancer].
Kishi K; Saito T; Mikamori M; Ohtsuka M; Furukawa K; Suzuki Y; Tei M; Tanemura M; Akamatsu H
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2069-2071. PubMed ID: 30692287
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer.
Binder D; Hackenthal M; Graseck L; Schweisfurth H; Schäper C; Krüll M; Temmesfeld-Wollbrück B; Suttorp N; Beinert T; Hellriegel KP
J Thorac Oncol; 2009 Sep; 4(9):1144-7. PubMed ID: 19609222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
